CDKN2A and ovarian cancer: For example, it has been shown that the overexpression of CCDC69 can activate the p14 ARF/MDM2/p53 pathway in ovarian cancer and that it is associated with a higher sensitivity to platinum drugs (Cui et al., 2019).